The 2017 Hormone Therapy Position Statement of The North American Menopause Society

The North American Menopause Society 2017 Hormone Therapy Position Statement Advisory Panel

Disclosures

The North American Menopause Society (NAMS). 2018;24(7):728-753. 

In This Article

Colorectal Cancer

Observational studies suggest a reduced risk of colorectal cancer in HT users, particularly if initiated early in menopause.[254] In the WHI across all ages, women on CEE + MPA therapy had a one-third (38%) lower risk of colorectal cancer than those on placebo, 10 cases per 10,000 person-years compared with 16 cases per 10,000 person-years, respectively (HR, 0.62; 95% CI, 0.43–0.89; Figure 1).[14] However, statistical significance was lost when included with the postintervention period. Further analysis of the WHI data, including postintervention data for women not taking the randomized treatment, found no strong evidence of a protective effect of either CEE + MPA or CEE-alone on risk of colorectal cancer.[14,143,255]

Key Points

  • Observational studies suggest a reduced incidence of colorectal cancer with HT, particularly if initiated early in menopause.

  • The use of CEE + MPA across all ages reduced colorectal cancer incidence during treatment.

  • Further analysis of the WHI data and postintervention data found no strong evidence of a protective effect of CEE-alone or CEE + MPA on risk of colorectal cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....